Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129180 · ClinicalTrials.gov registry record · Phase 1
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
A Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Pierluigi Porcu.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT01129180: Completed Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Pierluigi Porcu.
NCT01129180 is a Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma that has completed, run by Pierluigi Porcu. The registered enrollment target is 8 participants, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01129180, a Phase 1 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, has completed, sponsored by Pierluigi Porcu.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Bortezomib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with azacitidine in treating patients with relapsed or refractory T-cell lymphoma.
Conditions Studied
Interventions
- DRUG azacitidine
- DRUG bortezomib
- PROCEDURE Correlative studies
Study Locations (1)
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
What the finished NCT01129180 record still lists
NCT01129180 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (92% lower).
The record links to 10 conditions, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which azacitidine is the first listed.
NCT01129180 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT01129180 about?
NCT01129180 is a clinical study titled "Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma". RATIONALE: Bortezomib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with azacitidine in treating patients with relapsed or refractor...
What is the current status of trial NCT01129180?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2010-05. Estimated completion is 2012-12.
What conditions does trial NCT01129180 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Hepatosplenic T-cell Lymphoma.
What interventions are being tested in trial NCT01129180?
The interventions under investigation include: azacitidine (DRUG), bortezomib (DRUG), Correlative studies (PROCEDURE).
Who is sponsoring clinical trial NCT01129180?
This trial is sponsored by Pierluigi Porcu, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01129180 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01129180's enrollment target sits among peer trials
8 31st of 34 higher than 4 of 34 other Peripheral T-Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral T-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RECRUITING · Phase 1
-
Evaluate the Safety and Clinical Activity of HH2853
RECRUITING · Phase 1
-
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia